Trials / Completed
CompletedNCT03950427
PARQuit Smoking Cessation Intervention for Adults With Serious Mental Illness
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 131 (actual)
- Sponsor
- University of California, San Francisco · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a research study about a smoking cessation program tailored for adults with serious mental illness (SMI). The program uses a Videogame-based Physical (VIP) activity, smoking cessation counseling, and medication (bupropion),
Detailed description
The purpose of this study is to learn more about how adults with serious mental illness respond to a smoking cessation program combining a game-based Physical activity, counseling for smoking cessation, and a medication (bupropion or NRT) for smoking cessation. Study participants will receive counseling to quit smoking and a medication to help decrease cravings and withdrawal. Additionally, participants will be randomly selected to participate in either a game-based physical activity group or a game group where the participants sit to play the games. Participants will be in this study for 12 weeks total. There are 3 assessment visits (2 hours each) at the beginning of the study, 6 weeks after starting, and at the end of the 12 weeks. There will be 8 30- minute counseling sessions during the 12 weeks. The hour-long videogame groups will be held 3 times a week for 12 weeks (36 sessions). Upon completion of the 12-week program, there will be a 1-2 hour group interview. The total time commitment is 48 hours over the course of the 12-week study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Videogame-based physical activity | videogame-based physical activity |
| BEHAVIORAL | Sedentary videogame | sedentary videogame |
| DRUG | Bupropion | Bupropion |
| BEHAVIORAL | Counseling | Counseling for smoking cessation |
Timeline
- Start date
- 2019-07-08
- Primary completion
- 2025-07-30
- Completion
- 2025-07-30
- First posted
- 2019-05-15
- Last updated
- 2025-08-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03950427. Inclusion in this directory is not an endorsement.